U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C6H5O5S.Ca.H2O
Molecular Weight 436.425
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CALCIUM DOBESILATE MONOHYDRATE

SMILES

O.[Ca++].OC1=CC=C(O)C(=C1)S([O-])(=O)=O.OC2=CC=C(O)C(=C2)S([O-])(=O)=O

InChI

InChIKey=JMTQBGBMQZPWCS-UHFFFAOYSA-L
InChI=1S/2C6H6O5S.Ca.H2O/c2*7-4-1-2-5(8)6(3-4)12(9,10)11;;/h2*1-3,7-8H,(H,9,10,11);;1H2/q;;+2;/p-2

HIDE SMILES / InChI

Molecular Formula Ca
Molecular Weight 40.078
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C6H5O5S
Molecular Weight 189.166
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/7319004 | https://www.ncbi.nlm.nih.gov/pubmed/15312148

Calcium dobesilate (brand name Doxium) is a veno-tonic drug, which is widely prescribed in more than 60 countries from Europe, Latin America, Asia and the Middle East for three main indications: chronic venous disease, diabetic retinopathy and the symptoms of haemorrhoidal attack. This drugs also in the phase III of clinical trial is an effective adjuvant therapy, with an absence of significant side-effects, in patients with venous ulcers and stasis dermatitis. It was suggested, that the inhibitory effect of calcium dobesilate on platelet function is mediated through the cyclic AMP pathway, and probably through activation of adenyl cyclase.

Originator

Sources: Esteve A, Canal J, Laporte J. Ensayo clinico de la accion del 141-E sobre los tiempos de coagulacion y sangria. Medicina Clinica 1959; 33: 249
Curator's Comment: reference retrieved from https://www.ncbi.nlm.nih.gov/pubmed/16772766

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Doxium

Approved Use

Unknown
Primary
Doxium

Approved Use

Unknown
Primary
Doxium

Approved Use

Unknown
Primary
DICYNONE

Approved Use

ETHAMSYLATE is a haemostatic agent. It reduces bleeding from capillaries. Oral form prescribed for the management of blood loss in menorrhagia. Parenteral form used in surgery: prevention and treatment of pre-, per-, or postsurgical capillary haemorrhages in all delicate operations and in those affecting highly vascularised tissues: E.N.T., gynaecology, obstetrics, urology, odontostomatology, ophthalmology, plastic and reconstructive surgery. It also is used in paediatrics for the prevention of periventricular haemorrhages in premature babies.
PubMed

PubMed

TitleDatePubMed
Clinical and experimental studies on the action of ethamsylate on haemostasis and on platelet functions.
1980 Sep 15
Calcium dobesilate for chronic venous insufficiency: a systematic review.
2004 Mar-Apr
Therapeutic efficacy and mechanism of action of ethamsylate, a long-standing hemostatic agent.
2006 May-Jun
Patents

Sample Use Guides

Oral. Menorrhagia - The recommended dose is 500 mg 4 times/day during menstruation. Control of hemorrhage after surgery - The recommended dose is 250-500 mg 4-6 hourly as needed. Adults. Presurgical: 1-2 ampoules i.v. or i.m. (250-500mg) 1 hour before surgery. Persurgical: 1-2 ampoules i.v. Repeat the dosage if necessary. Postsurgical: 1-2 ampoules (250-500mg) every 4-6 hours as long as the risk of bleeding persists. Emergency cases, according to the severity of the case: 1-2 ampoules i.v. or i.m. every 4-6 hours as long as the bleeding risk persists. Local treatment: soak a swab with the contents of one ampoule and apply to haemorrhagic area, or in the tooth socket after dental extraction. The application may be repeated if necessary; it may be associated with oral or parenteral administration. Children. Half the adult dose. Neonatology: 10mg per kg body weight (0,1ml=12,5mg) injected intramuscularly within 2 hours of birth then every 6 hours for 4 days.
Route of Administration: Other
Under basal conditions, ethamsylate was unable to modify whole-blood platelet-leukocyte aggregation, but following whole-blood perfusion through a damaged vessel, ethamsylate produced a modest, but significant increase in platelet-leukocyte aggregates at concentrations 20-40 uM
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:14:24 GMT 2023
Edited
by admin
on Fri Dec 15 18:14:24 GMT 2023
Record UNII
M0ROX9374L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CALCIUM DOBESILATE MONOHYDRATE
EP  
Common Name English
CALCIUM DOBESILATE MONOHYDRATE [EP MONOGRAPH]
Common Name English
BENZENESULFONIC ACID, 2,5-DIHYDROXY-, CALCIUM SALT, MONOHYDRATE
Common Name English
BENZENESULFONIC ACID, 2,5-DIHYDROXY-, CALCIUM SALT, HYDRATE (2:1:1)
Common Name English
Code System Code Type Description
SMS_ID
100000091966
Created by admin on Fri Dec 15 18:14:24 GMT 2023 , Edited by admin on Fri Dec 15 18:14:24 GMT 2023
PRIMARY
PUBCHEM
45358052
Created by admin on Fri Dec 15 18:14:24 GMT 2023 , Edited by admin on Fri Dec 15 18:14:24 GMT 2023
PRIMARY
CAS
117552-78-0
Created by admin on Fri Dec 15 18:14:24 GMT 2023 , Edited by admin on Fri Dec 15 18:14:24 GMT 2023
PRIMARY
FDA UNII
M0ROX9374L
Created by admin on Fri Dec 15 18:14:24 GMT 2023 , Edited by admin on Fri Dec 15 18:14:24 GMT 2023
PRIMARY
CAS
117552-79-1
Created by admin on Fri Dec 15 18:14:24 GMT 2023 , Edited by admin on Fri Dec 15 18:14:24 GMT 2023
ALTERNATIVE
EVMPD
SUB11768MIG
Created by admin on Fri Dec 15 18:14:24 GMT 2023 , Edited by admin on Fri Dec 15 18:14:24 GMT 2023
PRIMARY
Related Record Type Details
ANHYDROUS->SOLVATE
PARENT -> SALT/SOLVATE